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Summary
C3 exhibits two common allotypic variants that may be separated by gel electrophoresis and
are calledC3 fast (C3 F) andC3 slow (C3 S) . C3 F, the less common variant, occurs at appreciable
frequencies only in Caucasoid populations (gene frequency = 0.20) . An increased prevalence
of the C3 F allele has been reported in patients with partial lipodystrophy, IgA nephropathy,
and Indian childhood hepatic cirrhosis. Studies of the genomic organization of the human C3
gene led to the identification of a single change (C to G) between C3 S and C3 F at nucleotide
364 in exon 3 . This leads, at the translation level, to the substitution of an arginine residue (positively
charged) in C3 S for a glycine residue (neutral) in C3 F. This substitution results in a polymorphic
restriction site for the enzyme HhaI . The resulting restriction fragment length polymorphism
(RFLP) was investigated using genomic DNA, amplified using the polymerase chain reaction;
there was absolute concordance between the genomic polymorphism and the distribution of
C3 S and C3 F in 50 normal subjects. The molecular basis ofa second structural polymorphism,
defined by the monoclonal antibody HAV 4-1, was also characterized . The polymorphic determinant
was identified at codon 314 in the exon 9 of the (3 chain where a leucine residue (HAV 4-1+)
is substituted for a proline residue (HAV 4-1 -) . Identification of the amino acid sequences of
these polymorphic variants will facilitate characterization ofpossible functional differences between
different allotypes of C3 . Three RFLPs (BamHI, EcoRl, and SstI) were located to introns in
the C3 gene. There was no allelic association between these three RFLPs, or between the RFLPs
and the C3 F/S polymorphic site. Genetic equilibration of these polymorphisms has occurred
within a gene of 41 kb.
T
he third component of complement, C3, occupies a cen-
tral position in the complement cascade and is quantita-
tively the major protein of the complement system, present
in plasma at a concentration of -1 g/liter. Its activation
results in the release of several split fragments with potent
chemotactic, opsonic, and anaphylatoxic properties. The pro-
teolytic cleavage of C3 is also required for the formation of
the cytolytic membrane attack complex .
Human C3 exhibits genetic polymorphism that was first
described by Weime and Demeulenaere (1) and Alper and
Propp (2) . The genetic variants of the protein are inherited
as autosomal codominant traits and are characterized using
prolonged agarose gel electrophoresis of fresh serum . In this
way, twocommon polymorphic forms have been found, desig-
nated C3 F and C3 S . The C3 S allele is most common in
all races in humans (2) . The C3 F allele is relatively frequent
in Caucasoids, less common in America Negroes (2), and
extremely rare in Orientals (3, 4) . More than 20 rare allo-
types have been characterized (5) by variations in their rela-
tive electrophoretic mobilities.
An additional common structural polymorphism was iden-
tified by Koch and Behrendt (6) based on the reactivity of
human C3 with a mouse mAb (HAV 4-1) that detected a
genetic variation not associated with any charge difference .
The two polymorphic systems, C3 S/F and HAV 4-1, are
closely related asHAV 4-1 usually, but not always, reacts with
the C3 F allotype. RFLPs have also been detected in the C3
gene (7, 8), but none distinguish between C3 S and C3 F
(9) . In humans, the only known functional difference between
the C3 S/F allotypes is binding to monocyte-complement
receptors (10), while in mice, C3 allotypes affect the degree
of activation of complement by zymosan (11) . Further, an
increased prevalence of the C3 F allotype has been found
in patients with several diseases, including Indian childhood
cirrhosis (12), IgA nephropathy (13, 14), and partial lipodys-
trophy (15) . The mechanism that is responsible for these as-
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lecular basis of the difference between the C3 allotypes is
important for theinterpretation ofany functional difference.
The entire amino acid sequence of humanC3, derivedfrom
cDNA sequencing (16) and the genomic organization (17)
have been published. In this report, we describe the molec-
ular basis of the difference betweenC3 S and C3 F. We have
also identified the epitope recognized by the mAb HAV 4-1
and the genomic localization of three RFLPs detected by
cleavage with different endonucleases. Theassociation of these
polymorphic markers in a population was determined and
indicated that there have been extensiveintragenic recombina-
tions within the C3 gene.
Materials and Methods
Serum andDNA Preparation.
￿
Fresh-frozen serum and EDTA
plasma were obtained from blood samples of 42 Caucasians and
threeChinese. At thesame time, genomicDNAwas isolated from
wholeblood. GenomicDNA samplesfrom five subjects who were
homozygous C3 FF were kindly donatedby D. Whitehouse (Galton
Laboratory, University College, London).
C3 Allogping andImmunoblotting.
￿
C3 allotyping wasperformed
on plasma samplesby means ofhigh voltage agarose gelelectropho-
resis as described by Teisberg (18). Immunoblotting was carried
out as reported by Koch et al. (19) .
Southern Blot Analysis.
￿
8-Fig aliquots of genomic DNA were
digested to completion with restriction endonucleases (EcoRI, SstI,
and BamHI) (Gibco-BRL, Uxbridge, Middlesex, UK) according
to the manufacturer's suggested conditions. TheDNA samples were
then subjected to electrophoresison a0.8% agarose gelandblotted
onto Hybound-N membranes (Amersham, Buckinghamshire) (20).
The blots were hybridized with a cDNA probe for C3, PC3.11
(16) (kindly provided by Dr. G.Fey, Scripps Clinic, La Jolla), which
was labeled by the random primer method (21). The filters were
then washed to high stringency (0.2 x SSC + 0.1% SDSat 65°C)
and exposed to film for 3-7 d at -70°C.
C3 SandC3 Fhblymorphism:PCR Amplification ofGenomicDNA,
Sequencing andRFLP. Two 18-mer oligonucleotides (5' ATCC-
CAGCCAACAGGGAG 3', positions 328-345, and 5' TAGCA-
GCTTGTGGTTGAC 3' complementary to nucleotide positions
514-531) (16) were chemically synthesized and designated oligos
EX3 andEX4, respectively. Thesewere used as primersin thePCR
to amplify 1 ug of genomic DNA using 1 U of Taq polymerise
(Perkin Elmer Cetus, Norwalk, CT). The DNA was denatured
at 94°C for 1 min, annealed at 56°C for 1 min, and extended at
72°C for 1 min, for 30 cycles.
The amplified DNA from six individuals were phenol/chloro-
form extracted, precipitated with 4 M NH4Ac and absolute eth-
anol, ligated into M13 vector, and sequenced according to the di-
deoxytermination method (22) using Sequenase (United States
Biochemical Corporation, Cleveland, OH). In RFLP studies, 60-80
ng ofamplifiedDNAwasdigested with therestriction endonuclease
Hhal. Cleaved fragments were then kinased using 'Y-[32P]ATP,
separated through a G-50 Sephadex column and precipitated with
absolute ethanol. The kinased DNA fragments were analyzed by
running throughan 8% denaturing polyacrylamide gel(PAGE) fol-
lowed by autoradiography.
HAV4-1 Polymorphism: PCR Amplification ofDNA and Allele-
Specific Oligonucleotide Hybridization. Two 21-mer oligonucleotides,
oligo EX9a (5' ATTGAGGATGGCTCGGGGGAG 3') and oligo
EX9b (5' CTGAGTGCAAGATGACGGTGG3'), complementary
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to nucleotide positions937-957and 1043-1063, respectively, were
used to amplify 1 lAg of genomic DNA as previously described.
Amplified DNA fragments from six individuals were subcloned
into Smal-digested M13mp8 andsequenced. PCR amplifiedgeno-
mic DNAs were run on a 1.5% agarose geland Southern blotted
(20). Thefilters were first hybridized overnightat 52°C with oligo
1 (5'GCAGAACCCCCGAGCAG3', corresponding to nucleotide
positions 993-1009; C at 1001) in oligo hybridization buffer (5 x
SSPE, 2% SDS, 50 wg/mlssDNA) andwashed in 6x SSCat room
temperature for 30 min, followed by two washes of 20 min each
in tetramethylammonium chloride (TMACI)' solution (3.0 M
TMACI, 50 mM Tris-HCI, pH 8.0, 2 mM EDTA, pH 8.0, 0.1%
SDS) at 53°C. The same blots were then stripped and hybridized
overnight at 50°C with oligo 2 (5'CTGCTCGGAGGTTCTGC3',
complementary to nucleotides 993-1009; A at 1001). The washes
were carried out as described above. Both oligonucleotides were
end-labeled using_y_[31P]ATP and T4 polynucleotide kinase (Gibco-
BRL) to a specific activity of 108 cpm/ug.
PCR Amplification andSequence ofS' Flanking Region ofthe C3
Gene. Two21-mer oligonucleotides, oligo A (5' TCTGACTCC-
CAGCCTACAGAG 3') and oligo B (5' GGAGGTGGGTTAG-
TAGCAGGA 3'), complementary to nucleotide positions443-463
bases upstream from thesignal peptide and32-52, respectively (17),
were used as primers to amplify genomic DNA from a normal in-
dividual allotypedC3 SS andanotherofallotype C3 FF. TheDNA
was denatured at 94°C for 1 min, annealed at 50°C for 1 min,
and extended at 72°C for 1 min. Amplifiedfragments were ligated
in M13 vector and sequenced as described above.
Results
Molecular Basis for C3 F and C3 S and C3 Allotyping by
RFLP. In the course of determining the genomic organi-
zation of the a chain of the human C3 gene (17), a single
base change (C to G) was identified in one of the genomic
clones (clone 6) at nucleotide 364, in exon 3, when com-
paredwith thepublishedcDNA sequence (16). This resulted,
at the translation level, in thesubstitution of an arginine res-
idue (positively charged), for a glycineresidue (neutral). We
therefore postulated that this chargedamino acid change could
explain the different electrophoretic mobility of C3 S and
C3 F. To test this hypothesis, we used PCR to amplify this
region from genomic DNA of six unrelated individuals of
known C3 allotype (two C3 FF, two C3 SS, and two C3
FS). Sequencing of the amplified DNA demonstrated abso-
lute concordance of this nucleotide polymorphism with the
C3 S and C3 F alleles (Fig. 1).
This nucleotide substitution generated also an RFLP with
the restriction endonuclease Hhal, which cleaves at the se-
quence GCGC in the C3 S allele (nucleotide positions 363-
366), but not GGGC in the C3 F allele. We therefore used
the PCR to amplify this region from the genomic DNA of
50 selected normal subjects with known C3 allotypes (7 C3
FF, 30 C3 SS, and 13 C3 FS). Digestion ofthe286-bp amplified
fragments with HhaI resulted in the generation of a single
uncleaved band from each C3 F allele and of two bands of
248 and 38 bases, respectively, from each C3 S allele (Fig.
'Abbreviations used in this paper. ASO, allele-specific oligonucleotide;
TMACI, tetramethylammonium chloride.
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￿
Charged amino acid difference between C3 F and C3 S . The
nucleotide guanine at position 364 in C3 F individuals was substituted
for cytosinein C3 S individuals. This results in the substitution ofglycine,
a neutral amino acid for arginine, a positively charged amino acid. The
autoradiograph is read from the bottom upwards, and the lanes reading
from left to right represent guanine, adenine, thymine, and cytosine (G,AT
and C, respectively) . The polymorphic nucleotide and codon is boxed to
the left of the lanes with the translated amino acid in bold (glycine [G]
and arginine [R]) .
2) . C3 allotyping determined by this method again concurred
absolutely with that derived by conventional high-voltage
agarose gel electrophoresis .
Identification ofthe Polymorphic Site Defined by the mAbHAV
4-1 . A second polymorphic determinant onhuman C3 was
detected by immunoblotting with the mAb HAV 4-1 (6) .
C3 S alleles are commonly HAV 4-1 negative, while C3 F
alleles are commonly HAV 4-1 positive. We studied 45 normal
individuals (three Chinese and 42 Caucasoids with the fol-
lowing gene frequency : C3 S = 0.81 ; C3 F = 0.19) by im-
munoblotting . We found two C3 S HAV 4-1-positive al-
leles, but no C3 F HAV 4-1-negative allele. Comparison of
the available DNA sequences (16, 17) spanning the coding
region from nucleotide positions 661-1179 of the cDNA se-
quence (previously identified byKoch and coworkers [23] as
the area containing the polymorphic determinant) revealed
a T to C transversion at nucleotide 1001, in the exon 9 of
the /3 chain, which resulted in the substitution of a leucine
residue by proline at amino acid position 314 (Fig. 3) . The
segregation ofthis polymorphic amino acid withmAb HAV
4-1 reactivity was confirmed by sequencing exon 9 from PCR-
amplified genomic DNA of six normal individuals with
known HAV 4-1 polymorphism (three C3 SSHAV 4-1 nega-
tive; two C3 FF HAV 4-1 positive ; and one C3 SS HAV 4-1
positive) . The subject heterozygous for the HAV 4-1 poly-
morphism (C3 SSHAV 4-1 positive) possessed both sequences.
We extended the analysis of this polymorphism by the use
of two allele-specific oligonucleotide (ASO) probes on PCR-
amplified DNA in 45 normal subjects (Fig . 4) . All were C3
allotyped as well as studied by immunoblotting with mAb
HAV 4-1 . The results of the ASO hybridization experiments
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Figure 2 .
￿
Determination ofC3 allotypes by RFLP. PCR-amplified DNA,
using primers EX3 and EX4, was digested with HhaI and kinased with
y[32p]ATP before running through an 8% denaturing polyacrylamide gel .
The autoradiograph shows that Hhal cleavage results in two bands of 248
and 38 by in subjects with the S allele, while an uncleaved band of 286
by is present in those with the F allele only. Individuals heterozygous (FS)
for both alleles show all three bands. SS, FS, and FF refer to the C3 allo-
types of individuals studied.
were concordant with those derived by the immunoblotting
of C3 .
Sequencing ofS' Flanking Region ofC3 F and C3 S .
￿
The
5' flanking region sequences from one C3 FF and one C3
SS individual were amplified by PCR, sequenced, and com-
pared . No differences were found up to 442 bases upstream
from the signal peptide.
Localization of Three RFLPs within the C3 Gene.
￿
Three
different RFLPs of the C3 gene were identified and localized
using probes for different regions of the C3 gene . We ana-
lyzed the frequency of these RFLPs in the same 45 normals
who had been allotyped by agarose gel electrophoresis and
immunoblotting (Table 1) . An EcoRI RFLP using the C3
cDNA probe pC3.11 revealed two allelic fragments of 5.2
and 5.6 kb (24), and was localized to intron 19 of the C3
ot chain by hybridization with subfragment probes from the
cDNA (data not shown) . The second RFLP, detected by the
restriction enzyme SstI, was originally described by Davies
et al. (7) . This polymorphism gave two allelic fragments of
12 and 9+3 kb in length, respectively, and was localized toFigure 3 .
￿
Amino acid change in the polymorphic site defined by the
mAb HAV 4-1. This results in a substitution of leucine (HAV 4-1 posi-
tive) for proline (HAV 4-1 negative) . The autoradiograph is read from
the bottom upwards, and the lanes reading from left to right represent
guanine, adenine, thymine, and cytosine(GAT, and C, respectively) . The
bold letters to the left of the sequences,-L andP, denote amino acid residues
leucine (CTC) and proline (CCC) .
intron 27 of the C3 rx chain, ti6 kb 3' to the EcoRI poly-
morphism, using apC3.11 subfragment probe spanning exons
28-29 (17) . A third RFLP was detected with the restriction
enzyme BamHI using a C3 cDNA probe spanning exons
11-14, and showed two allelic fragments of 2.8 and 2.5 kb.
This polymorphism was localized to an intron of the C3 a
chain, between exons 12 and 15 .
From the genomic structure of the human C3 gene (17),
we have determined that the physical distances between the
EcoRI and Sstl RFLPs in the ct chain and the C3 S/F poly-
morphism in the /3 chain is -15 and -19 kb, respectively
(Table 2 and Fig. 5) . The BamHI RFLP in the (3 chain is
Figure 4.
￿
Allele-specific oligonucleotide hybridization toDNA sequences
encoding theHAV 4-1 polymorphism . AmplifiedDNA was probed with
oligo 1 (lower sequence) and oligo 2 (upper sequence), and washed with
TMACI solution as described in the text . Individuals who were HAV 4-1
positive gave a positive signal with oligo 2, and those with an HAV 4-1
negative allele (i .e ., S- ) produced a signal with oligo 1 . Individuals who
were heterozygous for the alleles gave positive signals with both oligonu-
cleotides . F and S refer to the C3 allotypes, and the superscript symbols
represent negative or positive reactivity with the mAb HAV 4-1 .
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Shown is the gene frequency of the different C3 polymorphisms among
the cohort of 45 normal individuals .
<10 kb from the C3 S/F polymorphic site . The cosegrega-
tion of these RFLP markers with the protein variants was
analyzed in the panel of 45 normal individuals, and 29 were
informative . The data are summarized in Table 2 . From the
observed gene frequencies of the individual polymorphisms,
the expected frequency of individual C3 haplotypes was cal-
culated (Table 2) . This revealed near random association be-
tween alleles at the C3 S/F polymorphic site and other sites
in the ci and )3 chain within thehuman C3 gene . Although
not statistically significant, there was a trend towards allelic
association between the EcoRl 5.2-kb allele and the Sstl 12-kb
allele (data not shown) .
Discussion
The two common C3 variants, C3 S/F, may be separated
on the basis oftheir differing electrophoretic mobility through
agarose, which implies variation in surface charge between
the two allotypes . The very small difference in pl (0.05) be-
tween C3 S and C3 F, and their similar migration in PAGE
(25), suggests that the variation in charged amino acids be-
tween the two allotypes is limited to the substitution ofonly
one or two residues.
In studying the genomic structure of the /3 chain of the
human C3 gene, a C to G substitution was detected in the
sequence of one of the clones (clone 6) (17) when compared
with the published cDNA . The finding of a resultant charged
amino acid change led us to postulate the hypothesis that
thismay be the molecular basis ofthe difference between the
C3 S andC3 F allotypes. Conveniently, the nucleotide change
resulted in the predicted loss of a restriction site for HhaI
endonuclease, and we took advantage of this to measure the
concordance of the molecular and protein polymorphisms .
There was 100% concordance between C3 S/F allotypes in
50 individuals, determined by high-voltage agarose gel elec-
trophoresis, and genomic polymorphism determined using
HhaI . This finding suggested that the single nucleotide change
may be the molecular basis for the variation between C3 S
and C3 F, and this was supported by our other findings.
Koch and Behrendt (6) reported another polymorphic site,
characterized by a mAb, HAV 4-1, that was closely, but not
Molecular Basis of Polymorphisms of Human Complement Component C3
Table 1 . Gene Frequency ofHuman C3 Polymorphisms
Polymorphisms Frequency Polymorphisms Frequency
C3 S 0.81 C3 F 0.19
HAV 4-1 - 0.79 HAV 4-1+ 0.21
EcoRI (5.2 kb) 0.65 EcoRI (5.6 kb) 0.35
Sstl (12 kb) 0.68 Sstl (3 + 9 kb) 0.32
BarnHI (2.8 kb) 0.81 BamHI (2.5 kb) 0.19Shown is the frequency of the different haplotypes identified in the cohort of 45 normal individuals (58 informative chromosomes). The right hand
column shows the expected frequency of each haplotype calculated from the individual gene frequencies of the different polymorphisms.
absolutely, associated with the C3 S/F allotypic variation.
Further experiments showed that there was no charge differ-
ence between HAV 4-1-positive and HAV 4-1-negative allo-
types. The site ofthe polymorphism was located in the middle
of the (3 chain (23).
Two observations strongly suggest that all ofthe sequence
variation between C3 S and C3 F lies in the 0 chain 5' to
the polymorphism defined by HAV 4-1. First, although there
is close allelic association between the C3 S/F and HAV 4-1
polymorphisms, this is not absolute. 90% of C3 F alleles are
HAV 4-1 positive, and 10% are HAV 4-1 negative; the in-
verse applies to C3 S, where 98% are HAV4-1 negative and
2% HAV 4-1 positive (6). Second, there is no additional differ-
ence in electrophoretic mobility of HAV 4-1-positive and
-negative allotypes of`C3, which is not accounted for by the
C3 S/F polymorphism.
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￿
The restriction map of the C3 gene showing the positions
of the polymorphic sites (arrowed).
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Therefore, we sequenced exons 1-12 of the C3 gene from
the genomic clone 6, which included the entire region iden-
tified by Koch and coworkers (23) as containing the HAV
4-1 epitope. Comparisonofthe clone 6 coding sequence with
the published DNA sequences (16,17) showed only one differ-
ence: a T to C change in exon 9 (nucleotide position 1001).
This difference lies within the 20-kD fragment previously
identified (23) as containing the HAV 4-1 determinant. We
proceeded to study the correlation of this nucleotide change
with HAV 4-1 reactivity by sequencing of genomic DNA,
amplified by PCR, from individuals of known C3 S/F and
HAV 4-1 allotypes and by allele-specific oligonucleotide hy-
bridization. The sequences giving rise to the amino acid leu-
cine (CTC) and proline (CCC) segregated completely with
HAV 4-1 positivity and negativity.
These findings strongly support the hypothesis that the
difference between C3 S and C3 F may be explained solely
by the arginine/glycine polymorphism at position 102. In
addition, no difference between C3 S and C3 F was found
in the sequences of 5' flanking region of the gene up to 442
bases upstream from the signal peptide.
Three RFLPs were identified using the restriction en-
donucleases BamHI, EcoRI, and SstI. The polymorphic re-
striction sites were localized to the /3 chain (between exons
12 and 15) and introns 19 and 27 of the ci chain, respectively.
The BamHI RFLP comprised two bands of 2.5 and 2.8 kb
in the Q chain. Although there was strong allelic association
between the C3 S/F and HAV 4-1 polymorphisms, separated
by N5 kb, there was no significant allelic association between
either of these structuralpolymorphisms and the three RFLPs,
Table 2 . Haplotype
C3 F/S
allotype
Frequency
HAV 4-1
mAb
and Location of the
BamHI
(2.5/2.8 kb)
Polymorphic Sites in
EcoRI
(5.2/5.6 kb) (9
the C3 Gene
SstI
+ 3/12 kb) No.
Observed
frequency
Expected
frequency
1 S - 2.8 5.2 9+3 7 12 10.8
2 S - 2.8 5.6 9+3 5 8 5.8
3 S - 2.8 5.2 12 20 34 22.9
4 S - 2.8 5.6 12 7 12 12.3
5 S - 2.5 5.2 9+3 1 1.7 2.5
6 S - 2.5 5.2 12 6 10 5
7 S - 2.5 5.6 12 1 1.7 2.8
8 S - 2.5 5.6 9+3 2 3.5 1 .3
9 S + 2.8 5.2 12 1 1.7 6
10 S + 2.8 5.6 12 1 1.7 3.2
11 F + 2.8 5.2 9+3 1 1.7 0.6
12 F + 2.8 5.2 12 3 5 1.4
13 F + 2.8 5.6 12 3 5 0.7norbetweeneach oftheRFLPs. The distances between each
of the RFLPs were mapped and found to be between 6 and
10 kb of DNA. Despite these short distances, these poly-
morphisms have reached equilibrium in the Caucasoidpopu-
lation, andthis mayreflectthe great antiquityoftheC3 gene.
Similarfindings have been reported previously in other genes,
such as the /3 globin (26) and the phenylalanine hydroxylase
(27) genes.
Partial lipodystrophy (15), associated with autoantibody
production to neoantigens in the C3bBb C3 convertase en-
zyme, IgA nephropathy (13, 14), and Indian childhood he-
patic cirrhosis (12) have each been reported to be associated
with theC3 Fallele, suggesting that there maybe important
functional differences betweenthetwo common allotypic vari-
ants. There is one report that the C3 F allotype may have
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